Terra Alpha Investments LLC Has $1.13 Million Stake in Edwards Lifesciences Corporation $EW

Terra Alpha Investments LLC decreased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 39.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,283 shares of the medical research company’s stock after selling 8,767 shares during the quarter. Terra Alpha Investments LLC’s holdings in Edwards Lifesciences were worth $1,132,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter valued at about $25,000. Kohmann Bosshard Financial Services LLC acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $28,000. Hantz Financial Services Inc. lifted its stake in Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the period. Dorato Capital Management acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. Finally, Rakuten Securities Inc. lifted its stake in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,704,682.56. This trade represents a 51.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the completion of the sale, the vice president directly owned 33,682 shares in the company, valued at approximately $2,828,614.36. This represents a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 88,096 shares of company stock valued at $7,288,799. 0.31% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EW. Barclays reissued an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Wells Fargo & Company raised their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Wednesday, April 1st. Finally, Robert W. Baird raised their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Edwards Lifesciences Trading Up 0.0%

NYSE EW opened at $81.34 on Friday. The firm has a market cap of $46.84 billion, a P/E ratio of 43.27, a P/E/G ratio of 2.04 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock’s 50-day moving average is $81.50 and its 200-day moving average is $82.86. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.